Drugs / MK-3614
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01033643 | May → Dec 2009 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01104545 | Nov 2008 → May 2009 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3614 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01104545 ↗ |
| Route | Oral | “Participants received 0.25 mg of MK-3614 twice daily (BID) every 12 hours orally for 10 days.” NCT01033643 ↗ |